View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
October 6, 2021

Rho selects Medidata’s platform for clinical trials

Medidata’s end-to-end platform helps in reducing study build time, accelerating data reconciliation and clean-up.

Contract research organisation (CRO) Rho has selected Dassault Systèmes company Medidata’s decentralised clinical trial (DCT) capabilities for patient-focused approach to new drug development.

The company is using Medidata’s end-to-end platform to standardise its clinical trial platform to build the technology offerings related to DCTs.

This decentralised approach will help its clients to attract and secure more sponsor bids.

It also helps in reducing study build time, accelerating data reconciliation and clean-up, and saving money on data migrations and transfers.

This will allow Rho to provide cross-study data in decentralised trials and enables quick reporting of cross-domain.

Medidata partner and senior vice-president Joan Shaiman said: “Forward-thinking CROs, such as Rho, are rapidly making the necessary platform and accreditation investments to enable sponsors to move into a hybrid and/or fully decentralised approach to managing clinical trials.”

The company’s single platform helps to provide flexible support for future business growth.

This clinical technology capability will provide the sponsors with complete access to their clinical and operational data, which will help in advancing efforts to accelerate their development programmes.

Rho CEO Dr Laura Helms Reece said: “By partnering with Medidata we are further committing to sponsors that we can meet and exceed their future needs, especially as the market evolves from traditional clinical trials toward a more decentralised and patient-focused approach.

“This investment will give us an important competitive advantage as we strive to be ahead of the curve, as the industry continues to evolve in response to advancing technologies and the need for greater diversity and inclusion in clinical trials.

“A key element will be streamlined, real-time visibility into patient data and quality metrics throughout a decentralised trial, from inception to study conclusion.”

The company provides a complete range of clinical research services across the entire drug development process.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena